Table 3 Cure rates and missing patients in the all-treated target and clinically evaluable populations
Telavancin | Standard therapy | 95% CI for the difference (telavancin–standard therapy) | |
|---|---|---|---|
n/N (%) | n/N (%) | ||
All-treated target | |||
End-of-therapy visit | 11/15 (73%) | 15/16 (94%) | (–44.4, 7.8) |
Follow-up visit | 9/15 (60%) | 14/16 (88%) | (–53.6, 4.5) |
Test-of-cure visit | 8/15 (53%) | 11/16 (69%) | (–45.9, 18.5) |
Clinically evaluable | |||
End-of-therapy visit | 8/8 (100%) | 9/9 (100%) | (–26.1, 24.3) |
Follow-up visit | 7/8 (88%) | 9/9 (100%) | (–41.0, 19.1) |
Test-of-cure visit | 7/8 (88%) | 8/9 (89%) | (–35.5, 31.9) |
MRSA | 5/5 (100%) | 4/4 (100%) | - |
MSSA | 2/3 (67%) | 4/5 (80%) | - |